Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
212 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2014', provides an overview of the Pseudomonas Aeruginosa Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Pseudomonas Aeruginosa Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pseudomonas Aeruginosa Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pseudomonas Aeruginosa Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pseudomonas Aeruginosa Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pseudomonas Aeruginosa Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pseudomonas Aeruginosa Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Pseudomonas Aeruginosa Infections Overview 9 Therapeutics Development 10 Pipeline Products for Pseudomonas Aeruginosa Infections - Overview 10 Pipeline Products for Pseudomonas Aeruginosa Infections - Comparative Analysis 11 Pseudomonas Aeruginosa Infections - Therapeutics under Development by Companies 12 Pseudomonas Aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes 16 Pseudomonas Aeruginosa Infections - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Pseudomonas Aeruginosa Infections - Products under Development by Companies 21 Pseudomonas Aeruginosa Infections - Products under Investigation by Universities/Institutes 26 Pseudomonas Aeruginosa Infections - Companies Involved in Therapeutics Development 27 Achaogen Inc. 27 Actavis plc 28 Adenium Biotech ApS 29 AmpliPhi Biosciences Corporation 30 AnGes MG, Inc. 31 Aridis Pharmaceuticals LLC 32 AstraZeneca PLC 33 Biolytics Pharma 34 C3 Jian, Inc 35 ConjuGon, Inc. 36 FOB Synthesis, Inc. 37 GlycoMimetics, Inc. 38 GlycoVaxyn AG 39 Helix BioMedix, Inc. 40 Insmed Incorporated 41 KaloBios Pharmaceuticals, Inc. 42 LegoChem Biosciences, Inc 43 Lytix Biopharma AS 44 MedImmune, LLC 45 Melinta Therapeutics, Inc 46 Microbion Corporation 47 Microbiotix, Inc. 48 Northern Antibiotics Oy 49 Nosopharm SAS 50 Novabiotics Ltd 51 Novan, Inc. 52 Omnia Molecular Ltd. 53 PARI Pharma GmbH 54 Pfizer Inc. 55 Pherecydes Pharma SA 56 Phico Therapeutics Ltd. 57 Polyphor Ltd. 58 Procarta Biosystems Ltd 59 Sealife PHARMA GMBH 60 Sequoia Sciences, Inc. 61 Soligenix, Inc. 62 Spider Biotech 63 Syntiron LLC 64 Tetraphase Pharmaceuticals Inc. 65 Therametrics holding AG 66 Trana Discovery, Inc. 67 Vaxdyn, S.L. 68 Pseudomonas Aeruginosa Infections - Therapeutics Assessment 69 Assessment by Monotherapy Products 69 Assessment by Combination Products 70 Assessment by Target 71 Assessment by Mechanism of Action 73 Assessment by Route of Administration 75 Assessment by Molecule Type 77 Drug Profiles 79 (fosfomycin + tobramycin) - Drug Profile 79 AA-139 - Drug Profile 80 Aerucin - Drug Profile 81 AG-30/5C - Drug Profile 82 amikacin liposomal - Drug Profile 83 AmpliPHAGE-001 - Drug Profile 85 Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 86 APT-1026 - Drug Profile 87 AR-104 - Drug Profile 89 Biologic for Pseudomonas Aeruginosa Infection - Drug Profile 90 Cell Therapy for GBM and Pseudomonas Aeruginosa Infections - Drug Profile 91 Cephalosporin + Beta-Lactamase Inhibitor - Drug Profile 92 DasKloster-0274-01 - Drug Profile 93 dehydroleucodine - Drug Profile 94 Drug for Respiratory Tract Infections - Drug Profile 95 FSI-1671 - Drug Profile 96 FSI-1686 - Drug Profile 97 G-10 - Drug Profile 98 G-10KHc - Drug Profile 99 GMI-1051 - Drug Profile 101 GN-4474 - Drug Profile 102 HB-1345 - Drug Profile 103 HT-05 - Drug Profile 104 KB-001A - Drug Profile 105 LCB-100200 - Drug Profile 106 LTX-109 - Drug Profile 107 MBX-2359 - Drug Profile 109 MDN-0057 - Drug Profile 110 MDN-0058 - Drug Profile 112 MDN-0059 - Drug Profile 114 MDN-0060 - Drug Profile 116 Monoclonal Antibodies for Pseudomonas aeruginosa Infections - Drug Profile 118 NAB-7061 - Drug Profile 119 NAB-739 - Drug Profile 121 NAB-741 - Drug Profile 122 NBTI-5463 - Drug Profile 123 NOSO-95 - Drug Profile 124 NP-432 - Drug Profile 125 NVN-4428 - Drug Profile 126 Oligonucleotide for Gram Negative Infections - Drug Profile 127 Panaecin - Drug Profile 128 POL-7080 Follow-On - Drug Profile 129 PP-1131 - Drug Profile 130 pseudomonas aeruginosa conjugate vaccine - Drug Profile 132 Pseudomonas aeruginosa vaccine - Drug Profile 133 pseudomonas aeruginosa vaccine - Drug Profile 134 pseudomonas aeruginosa vaccine - Drug Profile 135 Pseudomonas aeruginosa vaccine - Drug Profile 136 pseudomonas and VAP conjugate vaccine - Drug Profile 137 PT-3.1 - Drug Profile 138 PT-3.33 - Drug Profile 139 RX-04 - Drug Profile 140 RX-05 - Drug Profile 141 RXP-763 - Drug Profile 142 RXP-766 - Drug Profile 144 RXP-770 - Drug Profile 146 RXP-793 - Drug Profile 148 RXP-808 - Drug Profile 149 RXP-873 - Drug Profile 150 SB-041 - Drug Profile 151 SB-204 - Drug Profile 152 SGX-942 - Drug Profile 153 SLP-0901 - Drug Profile 155 Small Molecule 2 to Inhibit Lectin B for Pseudomonas Aeruginosa Infections - Drug Profile 156 Small Molecule for Bacterial Infections - Drug Profile 157 Small Molecule for Chronic Wound Infection - Drug Profile 158 Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile 159 Small Molecule to Inhibit Lectin B for Pseudomonas Aeruginosa Infections - Drug Profile 160 Small Molecule to Inhibit Lectins for Pseudomonas Infections - Drug Profile 161 Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile 162 Small Molecules for Bacterial Infections - Drug Profile 163 Small Molecules for Bacterial Infections - Drug Profile 164 Small Molecules to Inhibit LasB for Pseudomonas Aeruginosa Infections - Drug Profile 165 Small Molecules to Inhibit LasR Receptor for Lung Infections and Pseudomonas aeruginosa Infections - Drug Profile 166 Small Molecules to Inhibit LpxC for Pseudomonas Aeruginosa Infections - Drug Profile 167 Small Molecules to Inhibit PqsD for Pseudomonas Aeruginosa Infections - Drug Profile 168 Small Molecules to Inhibit T3SS for Pseudomonas Aeruginosa Infections - Drug Profile 169 Small Molecules to Inhibit the Fatty Acid Synthesis for Pseudomonas Aeruginosa Infections - Drug Profile 170 Small Molecules to Inhibit Tryptophanyl-tRNA synthetase for Bacterial Infections - Drug Profile 171 Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile 172 tobramycin - Drug Profile 173 TP-433 - Drug Profile 174 TP-559 - Drug Profile 176 V-2L2MD - Drug Profile 177 VXD-002 - Drug Profile 178 Pseudomonas Aeruginosa Infections - Recent Pipeline Updates 179 Pseudomonas Aeruginosa Infections - Dormant Projects 195 Pseudomonas Aeruginosa Infections - Discontinued Products 197 Pseudomonas Aeruginosa Infections - Product Development Milestones 198 Featured News & Press Releases 198 Appendix 205 Methodology 205 Coverage 205 Secondary Research 205 Primary Research 205 Expert Panel Validation 205 Contact Us 206 Disclaimer 206
List of Tables Number of Products under Development for Pseudomonas Aeruginosa Infections, H2 2014 16 Number of Products under Development for Pseudomonas Aeruginosa Infections - Comparative Analysis, H2 2014 17 Number of Products under Development by Companies, H2 2014 19 Number of Products under Development by Companies, H2 2014 (Contd..1) 20 Number of Products under Development by Companies, H2 2014 (Contd..2) 21 Number of Products under Investigation by Universities/Institutes, H2 2014 23 Comparative Analysis by Late Stage Development, H2 2014 24 Comparative Analysis by Clinical Stage Development, H2 2014 25 Comparative Analysis by Early Stage Development, H2 2014 26 Products under Development by Companies, H2 2014 27 Products under Development by Companies, H2 2014 (Contd..1) 28 Products under Development by Companies, H2 2014 (Contd..2) 29 Products under Development by Companies, H2 2014 (Contd..3) 30 Products under Development by Companies, H2 2014 (Contd..4) 31 Products under Investigation by Universities/Institutes, H2 2014 32 Pseudomonas Aeruginosa Infections - Pipeline by Achaogen Inc., H2 2014 33 Pseudomonas Aeruginosa Infections - Pipeline by Actavis plc, H2 2014 34 Pseudomonas Aeruginosa Infections - Pipeline by Adenium Biotech ApS, H2 2014 35 Pseudomonas Aeruginosa Infections - Pipeline by AmpliPhi Biosciences Corporation, H2 2014 36 Pseudomonas Aeruginosa Infections - Pipeline by AnGes MG, Inc., H2 2014 37 Pseudomonas Aeruginosa Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2014 38 Pseudomonas Aeruginosa Infections - Pipeline by AstraZeneca PLC, H2 2014 39 Pseudomonas Aeruginosa Infections - Pipeline by Biolytics Pharma, H2 2014 40 Pseudomonas Aeruginosa Infections - Pipeline by C3 Jian, Inc, H2 2014 41 Pseudomonas Aeruginosa Infections - Pipeline by ConjuGon, Inc., H2 2014 42 Pseudomonas Aeruginosa Infections - Pipeline by FOB Synthesis, Inc., H2 2014 43 Pseudomonas Aeruginosa Infections - Pipeline by GlycoMimetics, Inc., H2 2014 44 Pseudomonas Aeruginosa Infections - Pipeline by GlycoVaxyn AG, H2 2014 45 Pseudomonas Aeruginosa Infections - Pipeline by Helix BioMedix, Inc., H2 2014 46 Pseudomonas Aeruginosa Infections - Pipeline by Insmed Incorporated, H2 2014 47 Pseudomonas Aeruginosa Infections - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2014 48 Pseudomonas Aeruginosa Infections - Pipeline by LegoChem Biosciences, Inc, H2 2014 49 Pseudomonas Aeruginosa Infections - Pipeline by Lytix Biopharma AS, H2 2014 50 Pseudomonas Aeruginosa Infections - Pipeline by MedImmune, LLC, H2 2014 51 Pseudomonas Aeruginosa Infections - Pipeline by Melinta Therapeutics, Inc, H2 2014 52 Pseudomonas Aeruginosa Infections - Pipeline by Microbion Corporation, H2 2014 53 Pseudomonas Aeruginosa Infections - Pipeline by Microbiotix, Inc., H2 2014 54 Pseudomonas Aeruginosa Infections - Pipeline by Northern Antibiotics Oy, H2 2014 55 Pseudomonas Aeruginosa Infections - Pipeline by Nosopharm SAS, H2 2014 56 Pseudomonas Aeruginosa Infections - Pipeline by Novabiotics Ltd, H2 2014 57 Pseudomonas Aeruginosa Infections - Pipeline by Novan, Inc., H2 2014 58 Pseudomonas Aeruginosa Infections - Pipeline by Omnia Molecular Ltd., H2 2014 59 Pseudomonas Aeruginosa Infections - Pipeline by PARI Pharma GmbH, H2 2014 60 Pseudomonas Aeruginosa Infections - Pipeline by Pfizer Inc., H2 2014 61 Pseudomonas Aeruginosa Infections - Pipeline by Pherecydes Pharma SA, H2 2014 62 Pseudomonas Aeruginosa Infections - Pipeline by Phico Therapeutics Ltd., H2 2014 63 Pseudomonas Aeruginosa Infections - Pipeline by Polyphor Ltd., H2 2014 64 Pseudomonas Aeruginosa Infections - Pipeline by Procarta Biosystems Ltd, H2 2014 65 Pseudomonas Aeruginosa Infections - Pipeline by Sealife PHARMA GMBH, H2 2014 66 Pseudomonas Aeruginosa Infections - Pipeline by Sequoia Sciences, Inc., H2 2014 67 Pseudomonas Aeruginosa Infections - Pipeline by Soligenix, Inc., H2 2014 68 Pseudomonas Aeruginosa Infections - Pipeline by Spider Biotech, H2 2014 69 Pseudomonas Aeruginosa Infections - Pipeline by Syntiron LLC, H2 2014 70 Pseudomonas Aeruginosa Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2014 71 Pseudomonas Aeruginosa Infections - Pipeline by Therametrics holding AG, H2 2014 72 Pseudomonas Aeruginosa Infections - Pipeline by Trana Discovery, Inc., H2 2014 73 Pseudomonas Aeruginosa Infections - Pipeline by Vaxdyn, S.L., H2 2014 74 Assessment by Monotherapy Products, H2 2014 75 Assessment by Combination Products, H2 2014 76 Number of Products by Stage and Target, H2 2014 78 Number of Products by Stage and Mechanism of Action, H2 2014 80 Number of Products by Stage and Route of Administration, H2 2014 82 Number of Products by Stage and Molecule Type, H2 2014 84 Pseudomonas Aeruginosa Infections Therapeutics - Recent Pipeline Updates, H2 2014 185 Pseudomonas Aeruginosa Infections - Dormant Projects, H2 2014 201 Pseudomonas Aeruginosa Infections - Discontinued Products, H2 2014 203
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
